ArticleFrontiers in nutrition2026
Growth and safety of infants with cow's milk allergy receiving a new hydrolyzed rice protein-based formula containing 2-fucosyllactose and lacto-N-neotetraose: protocol for a randomized clinical trial. The RIGHT-GO study.
Article in Frontiers in nutrition, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06633250 (Effect of a Hydrolyzed Rice Protein-based Formula on Growth, Tolerance, and Health-related Quality of Life in Infants With Cow's Milk Protein Allergy), which is not on this map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Effect of a Hydrolyzed Rice Protein-based Formula on Growth, Tolerance, and Health-related Quality of Life in Infants With Cow's Milk Protein Allergy: a Randomized Nutritional Clinical Study
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hydrolyzed rice formulas (HRF) are recommended by expert societies as a suitable option for the management of non-breastfed infants with cow's milk allergy (CMA). There is a growing trend towards the use of HRF driven by their plant-based source, appealing taste, and established safety and efficacy. Human milk oligosaccharides (HMOs) play a significant role in promoting gut and immune health of infants. There is currently no evidence regarding the growth and safety of infants receiving HRF containing two HMOs. The aim of the RIGHT-GO study is to assess the growth, safety and health-related quality of life of infants receiving a new HRF containing two manufactured HMOs, 2-fucosyllactose (2'FL) and lacto-N-neotetraose (LNnT). RIGHT-GO is a randomized controlled blinded multi-center trial (NCT06633250) conducted in Europe. Healthy full-term formula-fed infants ≤ 8 months of age with physician-diagnosed or suspected CMA will be randomized to receive either the new HRF (HRF-HMO) or an extensively hydrolyzed formula (eHF-HMO) for 4 months. Both formulas contain 1.5 g/L of 2'FL and LNnT (2:1 ratio). The primary objective is to demonstrate that infants with CMA fed the new HRF-HMO have age-appropriate growth that is non-inferior to that of infants with CMA fed a control eHF-HMO. The sample size required to demonstrate non-inferiority in weight-for-age z-score with a non-inferiority margin of -0.5 standard deviation is 104 infants (52 per group). Secondary outcomes include other growth parameters (length, head circumference, bone length), allergy symptoms, gastrointestinal tolerance, health-related quality of life, as well as adverse events and formula compliance. Assessments will take place at enrollment, then monthly until 4 months post-enrollment. The RIGHT-GO study will provide strong evidence on the growth, safety and gastrointestinal tolerance of the new HRF-HMO in infants with physician-diagnosed or suspected CMA. The results will be presented at scientific meetings and published in international peer-reviewed journals. Clinical trial registration: https://clinicaltrials.gov/study/NCT06633250, Identifier: NCT06633250.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.